Filtered By:
Condition: Thrombocytopenia

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 366 results found since Jan 2013.

Hemorrhagic stroke associated to COVID-19 infection in Mexico General Hospital
CONCLUSIONES: la HC se asocia a la infección por SARS-CoV-2 con mal pronóstico cuando se presenta. Los equipos de neurocirugía deben estar preparados para el tratamiento oportuno de estos pacientes.INTRODUCTION: In the current COVID-19 pandemic, there is a growing body of evidence that has identified the neurotropism of the SARS-CoV-2 virus and its neurological complications, including cerebrovascular disease, focusing mainly in ischemic and scarcely about hemorrhagic stroke (HS).OBJECTIVE: The objective of the study was to describe clinical, radiological, laboratory tests, and prognostic characteristics of patients wit...
Source: Cirugia y Cirujanos - August 5, 2021 Category: Surgery Authors: Gustavo Parra-Romero Ariatne Mar- Álvarez Jos é L Navarro-Olvera Aldo F Hern ández-Valencia Gustavo Aguado-Carrillo Jos é D Carrillo-Ruiz Source Type: research

Ischemic Stroke Due to Heparin-induced Thrombocytopenia During Severe COVID-19 Infection
Intern Med. 2022 Jul 5. doi: 10.2169/internalmedicine.9531-22. Online ahead of print.ABSTRACTA 53-year-old woman with severe coronavirus disease 2019 (COVID-19) pneumonia was admitted and treated with intravenous unfractionated heparin for thromboprophylaxis under general anesthesia with mechanical ventilation. She developed right hemiparesis after hospitalization due to a large hemorrhagic infarction. Her platelet count decreased from 243,000/μL at administration to 121,000/μL. Anti-platelet factor 4-heparin antibody testing was positive according to a latex immunoturbidimetric assay. She was therefore diagnosed with he...
Source: Internal Medicine - July 6, 2022 Category: Internal Medicine Authors: Yasutaka Murakami Shuhei Okazaki Makoto Yamamoto Rei Sakurai Jyunki Jinno Tatsuhiko Ozono Kensuke Ikenaka Yasufumi Gon Kenichi Todo Tsutomu Sasaki Haruhiko Hirata Akinori Uchiyama Hideki Mochizuki Source Type: research

Acute ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia post COVID-19 vaccination; a systematic review
One of the rare but potentially serious side effects of COVID-19 vaccination is arterial and venous thrombosis. Acute ischemic stroke (AIS) cases have been reported post COVID-19 vaccination. Herein, we systematically reviewed the reported cases of AIS after COVID-19 vaccination.
Source: Journal of the Neurological Sciences - June 20, 2022 Category: Neurology Authors: Zahra Kolahchi, MohammadHossein Khanmirzaei, Ashkan Mowla Tags: Review Article Source Type: research

Risk factors and characteristics of ischemic stroke in patients with immune thrombocytopenia: A retrospective cohort study
Immune thrombocytopenia (ITP), also known as idiopathic thrombocytopenic purpura, is an autoimmune disease characterized by a platelet count of
Source: Journal of Stroke and Cerebrovascular Diseases - August 31, 2022 Category: Neurology Authors: Xi Rong, Lidan Jiang, Meijie Qu, Shaonan Yang, Kun Wang, Liwei Jiang Source Type: research

A case of ischemic stroke and transient thrombocytopenia in a young female following adenoviral vector-based COVID-19 vaccination: Was the association incidental or causal?
We report a 23-year-old healthy female who developed seizures, altered sensorium, and left hemiparesis, 20 days after receiving the first dose of adenoviral vector-based COVID-19 vaccine "Covishield™." The patient had transient thrombocytopenia. The D-dimer level was 2460 ng/mL. Magnetic resonance imaging (MRI) demonstrated occlusion of M2 segment of the middle cerebral artery and cerebral infarction. Platelet factor-4 antibodies level was normal. Treatment with aspirin and antiepileptic drugs resulted in a remarkable recovery. This is the first Indian case report of ischemic stroke and transient thrombocytopenia followi...
Source: Primary Care - January 9, 2023 Category: Primary Care Authors: Shweta Pandey Ravindra Kumar Garg Pooja Tripathi Hardeep S Malhotra Neeraj Kumar Source Type: research

Early high-dose intravenous immunoglobulin for refractory heparin-induced thrombocytopenia with stroke: Two case reports
Heparin-induced thrombocytopenia (HIT) is a drug reaction caused by anti-platelet factor 4 (PF4)/heparin antibodies of the IgG class that activate through Fc γ receptors on platelets and monocytes. They consume platelets and increase thrombin generation.1 HIT occurs 5 to 14 days after the start of heparinization.2 Management of HIT involves discontinuing heparin and switching to an alternative anticoagulant to prevent thrombosis and normalize platelet l evels.3–5 Autoimmune HIT (aHIT), which maintains marked heparin-independent platelet activation even after discontinuing heparin, has recently attracted attention.
Source: Journal of Stroke and Cerebrovascular Diseases - January 24, 2023 Category: Neurology Authors: Naoki Makita, Tomoyuki Ohara, Yukiko Tsuji, Tetsuhiro Ueda, Takuma Nakamura, Toshiki Mizuno, Masahiro Makino Tags: Case Report Source Type: research

Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis.
CONCLUSIONS: According to the results of this analysis, DAPT might have to be cautiously be used following PCI in a population of patients with thrombocytopenia at baseline due to the significantly higher bleeding rate including gastro-intestinal, intra-cranial bleeding and hemorrhagic stroke. Hence, special care might have to be taken when considering anti-platelet agents following PCI in these high risk patients. However, considering the present limitations of this analysis, this hypothesis will have to be confirmed in future trials. PMID: 32334636 [PubMed - as supplied by publisher]
Source: BMC Pharmacology and Toxicology - April 27, 2020 Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cerebrovascular Disease and HIV in Singapore: A Single-Centre Study (P1.325)
Conclusions: Prevalence of CVS risk factors was significant in our population. Stroke in HIV patients may result from other disease mechanisms and carries significant mortality and morbidity. Fever at presentation suggests an infective etiology.Disclosure: Dr. Gan holds stock and/or stock options in a company which sponsored research in which Dr. Gan was involved as an investigator. Dr. Saini has nothing to disclose. Dr. Lee has nothing to disclose. Dr. Ng has nothing to disclose. Dr. Tan has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Gan, E., Saini, M., Lee, C.-C., Ng, O.-T., Tan, K. Tags: HIV/AIDS Source Type: research

Blood Cell Disorders and the Nervous System
This article discusses the epidemiology, diagnosis, treatment, and prevention of neurologic complications of common and rare blood cell disorders. recent findings A growing number of preventive treatment options are available for stroke in sickle cell disease. Paroxysmal nocturnal hemoglobinuria and immune thrombocytopenia can lead to stroke. Thrombotic thrombocytopenic purpura frequently causes neurologic symptoms and should be considered in the differential diagnosis of a patient with neurologic symptoms, thrombocytopenia, and hemolytic anemia. Polycythemia vera and essential thrombocythemia are rare causes of stroke....
Source: CONTINUUM: Lifelong Learning in Neurology - June 1, 2020 Category: Neurology Tags: REVIEW ARTICLES Source Type: research